Abstract:Over the past decades, it has become apparent that a human body is inextricably intertwined with the microbiome. The latter exchanges metabolites with a host’s organism, protects it from infectious agents and is necessary for the normal immune system development. Microbiome can also respond to any changes in a host body and becomes altered («dysbiotic») during diseases or pathological conditions. The exchange between the host and the microbiome occurs constantly, it is bidirectional and integral both during a healthy state and during disease. Therefore, there is considerable interest in microbiome‐based therapy (BM) for a wide range of human diseases. The microbiome is a multi‐level ecological system, and any approach that alters any component of that system can be considered as MBT, or in other words, microbiota therapy. Recently, significant progress has been made in the development of live biologics that help to restore normal gut microbiota and treat various diseases, including Clostridium difficile infection (CDI). Currently, the most common types of MBT are: 1) fecal microbiota transplantation (FMT); 2) a certain consortium of known microbes delivered orally or instilled into the gastrointestinal tract; 3) addition of microbial metabolites (for example, short‐chain fatty acids, butyrate). Interest in the intestinal microbiota has especially increased after the establishment of excellent therapeutic efficacy of FMT at CDI, as well as other intestinal diseases and some extraintestinal diseases that are difficult to treat with traditional methods. This promoted the study of the effectiveness and safety of MBT, such as classical and defined (selective) TFM, treatment with faecal spores or non‐toxigenic strains of C. difficile, classical or new commensal probiotics, bacteriophages or recombinant live biotherapeutic products. This completely new line of treatment, despite its short history, has ushered in a new era in the improvement of treatment aimed at intestinal and metabolic disorders.

Escape Velocity – The Launch of Microbiome Therapies

Fecal microbiota transplantation: current challenges and future landscapes

Gut microbiome therapy: fecal microbiota transplantation vs live biotherapeutic products

The Impact of Regulatory Policies on the Future of Fecal Microbiota Transplantation

Update on Fecal Microbiota Transplantation 2015: Indications, Methodologies, Mechanisms, and Outlook

Fecal Microbiota Transplantation: An Update on Clinical Practice

Clinical Application and Potential of Fecal Microbiota Transplantation

Fecal Microbiota Transplantation: Current Applications, Effectiveness, and Future Perspectives

Current insights into microbiome-based therapy. Review

Fecal microbiota transplantation and emerging applications

Encapsulated Fecal Microbiota Transplantation: Development, Efficacy, and Clinical Application

An update on fecal microbiota transplantation for the treatment of gastrointestinal diseases

Assessing Engraftment Following Fecal Microbiota Transplant

Fecal microbiota transplantation: History, procedure and regulatory considerations

Fecal microbiota transplantation: in perspective

Fecal Microbiota Transplantation: Indications, Methods, and Challenges

Fecal microbiota transplantation: effectiveness, complexities, and lingering concerns

Standards for fecal microbiota transplant: Tools and therapeutic advances

Impacts of Gut Microbiota on the Immune System and Fecal Microbiota Transplantation as a Re-Emerging Therapy for Autoimmune Diseases

Fecal microbiota transplantation as novel therapy in gastroenterology: A systematic review

Current Status and Future Therapeutic Options for Fecal Microbiota Transplantation